News related to Dilaudid (Hydromorphone) and/or conditions it is approved for
Neuromed Completes Enrollment For Phase 3 Chronic Low Back Pain Clinical Trial Of NMED-1077 Source: Pain / Anesthetics News From Medical News Today [2008.11.21] Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announced it has completed enrollment in the pivotal Phase 3 chronic low back pain clinical trial of NMED-1077 (OROS(R) Hydromorphone) for the treatment of chronic moderate-to-severe pain in opioid tolerant patients.